Liver Cancer Disparities in American Indian and Alaska Native Persons
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Cirrhosis, any etiology, or chronic HBV infection
• High risk of HCC
• Age 18-75
• Competent to provide informed consent
Locations
United States
Oklahoma
Cherokee Nation Health Service
RECRUITING
Tahlequah
Contact Information
Primary
Jennifer R Harry
jharry@medicine.washington.edu
206-616-0397
Backup
Stephanie Y Park
sypark22@uw.edu
206-744-7050
Time Frame
Start Date: 2022-04-01
Estimated Completion Date: 2026-09-01
Participants
Target number of participants: 200
Treatments
Active_comparator: Ultrasound + AFP
Screening by abdominal ultrasound + serum AFP testing at 0, 6 and 12 months
Active_comparator: aMRI + AFP
Screening by abbreviated MRI of the abdomen + serum AFP testing at 0, 6 and 12 months
Related Therapeutic Areas
Sponsors
Collaborators: Alaska Native Tribal Health Consortium, Cherokee Nation Health Services, National Cancer Institute (NCI)
Leads: University of Washington